THEMIS2 and B-cell chronic lymphocytic leukemia: In this cohort, elevated expression of THEMIS2 was associated with inferior TFS, both on the mRNA level (high expression, median TFS ≈10 months, versus low expression, median TFS NR; P = 0.007) (Figure 5C) and on the protein level (high abundance, median TFS ≈4 months, versus low abundance, median TFS NR; P < 0.0001) (Figure 5D).22 In the second dataset, assembled by Knisbacher et al, bulk RNA sequencing and clinical data were available for 556 treatment-naïve CLL patients.29 Baseline characteristics of these patients are listed in Suppl.